Cetuximab is an anti-EGFR antibody commonly used to treat CRC without KRAS proto-oncogene GTPase (KRAS), NRAS proto-oncogene GTPase (NRAS), or B-Raf proto-oncogene serine/threonine kinase (BRAF) mutations [262]. This evidence concerns the gene NRAS and colorectal carcinoma.